glp-1 oral dosage Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are GLP-1 Medications for Weight Loss:

High-risk groups can exhibit different responses after GLP-1 cessation

Blood donation is one of the most meaningful ways to save lives

Other significant considerations include: Injection site reactions (for subcutaneous formulations) Hypoglycaemia risk (particularly if used alongside other glucose-lowering medications) Pancreatitis (rare but serious) Gallbladder disease (including gallstones and cholecystitis) Dehydration leading to acute kidney injury (particularly with severe gastrointestinal side effects) Diabetic retinopathy complications (particularly noted with semaglutide in diabetes patients) Potential thyroid effects (medullary thyroid carcinoma risk in animal studies, though human relevance remains unclear) A Parkinson's-specific concern is that GLP-1 receptor agonists delay gastric emptying, which may further impair levodopa absorption and potentially worsen motor fluctuations or 'OFF' periods in patients on this medication

One of those potential side effects is excessive urination and thirst, which may affect up to 70 percent of individuals who take lithium long-term, according to research

10.1016/j.pmpp.2005.03.007 179 ZeierJ.PinkB.MuellerM

Bharucha AE, Kudva YC, Prichard DO